Home/Investors/Venrock

Venrock

Biotech Investor · 7 portfolio companies

Portfolio

7

Combined Value

$356.5M

Focus Areas

12

Top Stage

Pre-clinical

Investment Focus

Metabolic Disease Cardiovascular Disease Digital Health Psychiatry Neuroscience Neurodegenerative Diseases Alzheimer's Disease Rare Genetic Neurodevelopmental Disorders Neurology Ophthalmology Oncology Rare Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
Nautilus Biotechnology	Early Access / Beta Testing	$356.5M	—
Play Health	phase-2	—	Metabolic Disease, Cardiovascular Disease
Lusaris Therapeutics	phase-1	—	Psychiatry, Neuroscience
Korsana Biosciences	Pre-clinical	—	Neurodegenerative Diseases, Alzheimer's Disease
Mahzi Therapeutics	Pre-clinical	—	Rare Genetic Neurodevelopmental Disorders
Iris Medicine	Pre-clinical	—	Neurology, Ophthalmology
AIRNA	Pre-clinical	—	Oncology, Rare Diseases

Frequent Co-Investors

ARCH Venture Partners1 shared General Catalyst1 shared Oak HC/FT1 shared HealthCap1 shared Droia Ventures1 shared Forbion1 shared Sanofi Ventures1 shared RA Capital Management1 shared